Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Main Street Financial Solutions LLC

Main Street Financial Solutions LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,681 shares of the company’s stock after acquiring an additional 381 shares during the period. Main Street Financial Solutions LLC’s holdings in Novo Nordisk A/S were worth $438,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Kingsview Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 835.9% in the 1st quarter. Kingsview Wealth Management LLC now owns 21,208 shares of the company’s stock valued at $2,723,000 after purchasing an additional 18,942 shares in the last quarter. Blair William & Co. IL boosted its stake in Novo Nordisk A/S by 12.9% during the 1st quarter. Blair William & Co. IL now owns 71,036 shares of the company’s stock valued at $9,121,000 after acquiring an additional 8,126 shares during the last quarter. Great Lakes Retirement Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth $791,000. Nwam LLC increased its position in shares of Novo Nordisk A/S by 51.3% in the 1st quarter. Nwam LLC now owns 3,831 shares of the company’s stock worth $488,000 after purchasing an additional 1,299 shares during the last quarter. Finally, First Foundation Advisors raised its stake in shares of Novo Nordisk A/S by 3.1% in the 1st quarter. First Foundation Advisors now owns 7,416 shares of the company’s stock valued at $952,000 after purchasing an additional 223 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on NVO. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Trading Down 1.5 %

Shares of NVO stock opened at $105.35 on Friday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm has a market capitalization of $472.76 billion, a PE ratio of 34.09, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The stock has a fifty day moving average of $119.68 and a two-hundred day moving average of $129.92. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.